Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVNNASDAQ:CMPSNASDAQ:IDYANASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.74-3.2%$21.52$14.69▼$55.70$1.61B1.181.23 million shs2.87 million shsCMPSCOMPASS Pathways$4.34-6.1%$3.41$2.49▼$8.54$402.96M2.27829,659 shs1.22 million shsIDYAIDEAYA Biosciences$19.15-2.4%$17.66$13.45▼$44.42$1.68B0.261.01 million shs1.60 million shsINDVIndivior$11.29-1.3%$10.22$7.33▼$18.59$1.56B0.981.01 million shs509,100 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-2.99%-19.35%-23.88%-60.43%-59.38%CMPSCOMPASS Pathways-6.06%+12.44%+28.40%-4.41%-44.85%IDYAIDEAYA Biosciences-2.45%+11.99%+5.34%-11.97%-53.29%INDVIndivior-1.31%+2.36%+28.15%+25.58%-33.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven3.487 of 5 stars4.51.00.00.02.74.20.6CMPSCOMPASS Pathways2.2109 of 5 stars3.61.00.00.04.00.80.6IDYAIDEAYA Biosciences3.7796 of 5 stars3.51.00.04.44.01.70.0INDVIndivior3.2742 of 5 stars3.63.00.00.02.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$59.46277.89% UpsideCMPSCOMPASS Pathways 3.17Buy$20.20365.44% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27183.41% UpsideINDVIndivior 3.25Buy$15.0032.86% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, INDV, BHVN, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/13/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/20/2025BHVNBiohavenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/7/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$69.00 ➝ $63.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ACMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AIDYAIDEAYA Biosciences$7M239.60N/AN/A$12.10 per share1.58INDVIndivior$1.17B1.33$2.29 per share4.94N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%N/ACMPSCOMPASS Pathways-$118.46M-$1.99N/AN/AN/AN/A-63.85%-51.97%8/7/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)INDVIndivior$2M-$0.31N/A6.60N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)Latest CMPS, INDV, BHVN, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/3/2025Q4 2024BHVNBiohaven-$1.56-$1.85-$0.29-$1.85$100.00 millionN/A2/27/2025Q4 2024CMPSCOMPASS Pathways-$0.62-$0.63-$0.01-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohavenN/A2.892.89CMPSCOMPASS Pathways0.158.918.91IDYAIDEAYA BiosciencesN/A14.9722.93INDVIndiviorN/A0.830.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%CMPSCOMPASS Pathways46.19%IDYAIDEAYA Biosciences98.29%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%CMPSCOMPASS Pathways4.25%IDYAIDEAYA Biosciences2.50%INDVIndiviorN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239102.11 million84.94 millionOptionableCMPSCOMPASS Pathways12092.85 million65.51 millionOptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableCMPS, INDV, BHVN, and IDYA HeadlinesRecent News About These CompaniesIndivior PLC (NASDAQ:INDV) Shares Acquired by Stonepine Capital Management LLCMay 20 at 6:47 AM | marketbeat.comMadison Avenue Partners LP Reduces Stake in Indivior PLC (NASDAQ:INDV)May 16, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Holdings Lifted by Newtyn Management LLCMay 16, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes Position in Indivior PLC (NASDAQ:INDV)May 13, 2025 | marketbeat.comFund 1 Investments LLC Grows Stock Position in Indivior PLC (NASDAQ:INDV)May 11, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Shares Bought by Tudor Investment Corp ET ALMay 11, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Stock Holdings Raised by Deerfield Management Company L.P. Series CMay 10, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Invests $1.69 Million in Indivior PLC (NASDAQ:INDV)May 9, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Short Interest UpdateMay 5, 2025 | marketbeat.comAlta Fundamental Advisers LLC Acquires 75,000 Shares of Indivior PLC (NASDAQ:INDV)May 5, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Shares Purchased by Ardsley Advisory Partners LPMay 5, 2025 | marketbeat.comFoursixthree Capital LP Takes Position in Indivior PLC (NASDAQ:INDV)May 3, 2025 | marketbeat.comCannabis Stocks To Watch Now - April 29thMay 1, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 376,955 Shares of Indivior PLC (NASDAQ:INDV)April 30, 2025 | marketbeat.comMelqart Asset Management UK Ltd Grows Position in Indivior PLC (NASDAQ:INDV)April 29, 2025 | marketbeat.comBoothbay Fund Management LLC Raises Stock Holdings in Indivior PLC (NASDAQ:INDV)April 29, 2025 | marketbeat.comFY2025 EPS Estimates for Indivior Boosted by Northland CapmkApril 29, 2025 | marketbeat.comIndivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsApril 28, 2025 | finance.yahoo.comIndivior: Trying To Break AddictionApril 28, 2025 | seekingalpha.comXTX Topco Ltd Sells 110,663 Shares of Indivior PLC (NASDAQ:INDV)April 28, 2025 | marketbeat.comWhat is Northland Capmk's Forecast for Indivior Q3 Earnings?April 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, INDV, BHVN, and IDYA Company DescriptionsBiohaven NYSE:BHVN$15.74 -0.52 (-3.17%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$16.02 +0.28 (+1.78%) As of 05/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.COMPASS Pathways NASDAQ:CMPS$4.34 -0.28 (-6.06%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$4.28 -0.06 (-1.50%) As of 05/21/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.IDEAYA Biosciences NASDAQ:IDYA$19.15 -0.48 (-2.45%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$19.15 0.00 (0.00%) As of 05/21/2025 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Indivior NASDAQ:INDV$11.29 -0.15 (-1.31%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$11.30 +0.01 (+0.09%) As of 05/21/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? $30B AI Opportunity: Will It Power Meta’s Next Surge? Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
